Rapamune
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Facial Angiofibroma
Conditions
Facial Angiofibroma
Trial Timeline
Oct 1, 2013 → Jul 1, 2016
NCT ID
NCT01853423About Rapamune
Rapamune is a phase 1 stage product being developed by Pfizer for Facial Angiofibroma. The current trial status is completed. This product is registered under clinical trial identifier NCT01853423. Target conditions include Facial Angiofibroma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00044720 | Approved | Completed |
| NCT01853423 | Phase 1 | Completed |
| NCT00286156 | Phase 1/2 | Completed |
| NCT00195481 | Approved | Completed |
| NCT00470665 | Phase 3 | Completed |
Competing Products
13 competing products in Facial Angiofibroma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BOTOX | AbbVie | Approved | 85 |
| OnabotulinumtoxinA + KYBELLA | AbbVie | Approved | 85 |
| BOTOX®/VISTABEL® | AbbVie | Approved | 85 |
| Erenumab Prefilled Syringe | Amgen | Approved | 84 |
| EMLA Cream | Sanofi | Phase 3 | 76 |
| Diflucortolone valerate (BAY866146) | Bayer | Pre-clinical | 20 |
| Botulinum toxin type A | Ipsen | Phase 3 | 74 |
| IPN10200 + IPN10200 Placebo + Dysport | Ipsen | Phase 1/2 | 38 |
| IPN59011 + Azzalure + Placebo | Ipsen | Phase 1 | 30 |
| Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4) | Baxter | Phase 2 | 49 |
| Metyrosine + Placebo | Bausch Health | Phase 2 | 47 |
| FMX103 minocycline foam 1.5% + Vehicle foam | Vyne Therapeutics | Phase 3 | 69 |
| FMX103 minocycline foam 1.5% + Vehicle foam | Vyne Therapeutics | Phase 3 | 69 |